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Abstract
Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine
tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro
and in vivo effects of everolimus in combination with octreotide in MTC. Two patients with progressive metastatic MTC and high calci-
tonin levels were treated with everolimus 5–10 mg/day. Both patients were under treatment with octreotide LAR at the study entry. An
in vitro study was also performed to assess everolimus effects on MTC cell lines (TT and MZ-CRC-1 cells). A tumour response was
observed in both patients. Serum calcitonin decreased by 86% in patient 1 and by 42% in patient 2. In TT and MZ-CRC-1 cells,
everolimus induced a significant dose-dependent inhibition in cell proliferation. This effect seems to be related to a cell cycle arrest in
G0/G1 phase in both cell lines and to the induction of cellular senescence in TT cells. Everolimus in combination with octreotide may be
active as anti-tumour therapy in patients with progressive metastatic MTC, suggesting to further evaluate this agent in MTC patients in
a large prospective study.
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Introduction
Medullary thyroid cancer (MTC) is a neuroendocrine tumour orig-
inating from the C cells within the thyroid gland [1, 2]. Medullary
thryroid cancer has been demonstrated to express somatostatin
receptors, which are the molecular target of somatostatin ana-
logues [3, 4]. Octreotide and lanreotide, two somatostatin ana-
logues exerting both anti-secretory and anti-tumour activity in dif-
ferent types of neuroendocrine tumours, have shown low efficacy
in MTC [5–8]. This is likely explained by the fact that octreotide
and lanreotide, the currently available somatostatin analogues, act
mainly through the somatostatin receptor subtype 2 which seems
not so relevant for obtaining anti-proliferative effects in MTC [9].
Recently, the AKT-mTOR pathway has been demonstrated to be
overexpressed in neuroendocrine tumours [10, 11]. In addition,
everolimus (RAD001), a novel agent that antagonizes mTOR, has
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been reported to induce encouraging results in terms of neuroen-
docrine tumour control both in vitro [12, 13] and in vivo [14, 15].
Everolimus is able to disrupt an important survival pathway of
cancer cells thus triggering apoptosis in several tumour cell mod-
els [16]. However, alternative mechanisms of programmed cell
death have been recently described in papillary thyroid cancer
(PTC) cells exposed to everolimus. In fact, it was demonstrated
that everolimus can sensitize PTC cells to radiation and
chemotherapy through the induction of autophagic cell death [17].
Medullary thyroid cancer may be an optimal model to evaluate
the efficacy of everolimus for different reasons: (a) this tumour
expresses the  specific molecular pathway targeted by everolimus;
(b) newly  discovered rearranged during transfection (RET) and
VEGF inhibitors are now under evaluation in clinical trials and prom-
ises to be effective in these patients. However, there is no chemother-
apy or biological therapy which is now available to effectively treat
patients with metastatic or relapsing MTC; (c) calcitonin and carci-
noembryonic antigen (CEA) are highly sensitive and specific markers
of MTC progression and both can help to reliably evaluate the
response to everolimus; (d) a recent in vitro study showed a potent
inhibitory effect of everolimus on cell proliferation of MTC cells [18].
Nowadays no data are available concerning the activity of
everolimus, either alone or in combination with octreotide, in
patients with MTC. The objective of this study was to assess the in
vivo and in vitro efficacy of this drug in patients with progressive
metastatic MTC.
Materials and methods
Clinical study
Everolimus was obtained by Novartis Farma S.p.A. (Origgio, Italy) for com-
passionate treatment in two patients with progressive metastatic MTC,
according to Novartis guidelines for compassionate use. Everolimus was
started at the dose of 10 mg a day in one patient and 5 mg a day in one other
and was lowered to 5 mg a day, 5 mg every other day or discontinued
according to toxicity. Both patients were under treatment with octreotide LAR
30 mg a month at the study entry and received everolimus in combination.
Clinical symptom evaluation and calcitonin and CEA measurement were
performed monthly. Bone metastases were evaluated by contrast-enhanced
MRI of vertebral bodies in patients 1 and 2. Lymph node metastases were
evaluated by contrast-enhanced CT scan and colour Doppler ultrasonogra-
phy in patient 2. Fluoro-18 deoxyglucose positron emission tomography
(FDG-PET) was also performed in both patients.
Written informed consent of both patients was obtained. The study was
conducted in accordance with the Declaration of Helsinki, adhering to all
local regulatory guidelines.
Hormone assays
Serum calcitonin concentrations, evaluated during clinical study, were
determined by a commercially available IRMA (Byk Gulden Italia S.p.A.,
Milan, Italy). The detection limit of the assay was 0.7 pg/ml. The intraassay
conduction velocities (CVs) were 6.2% and 2.3% at serum concentrations
of 50 and 200 pg/ml, respectively. The interassay CVs were 6.9% and 4.2%
at serum calcitonin concentrations of 50 and 200 pg/ml, respectively.
Drug preparation and cell line cultures
Everolimus was kindly provided by Novartis Pharma (Basel, Switzerland),
and dissolved in dimethyl sulfoxide (DMSO) to yield a stock solution of 
10 mM, which was stored at 20C. TT and MZ-CRC-1, both human MTC
cell lines, were obtained from Prof. Lips (University of Utrecht, The
Netherlands). TT and MZ-CRC-1 cells were grown at 37C in F-12 with
Kaighn’s Modification medium containing 10% foetal bovine serum, 2 nM
glutamine and 105 U/l penicillin–streptomycin and maintained in a humid-
ified atmosphere of 5% CO2. The cells were grown in 75 cm2 flasks and
passaged once every 4–7 days on a 1:2 split.
Cell viability assay
TT and MZ-CRC-1 cells were plated in 96-well plates at a density of 3.5  104
per well. The following day, cell culture medium of both cell lines was
replaced with medium containing various concentrations of everolimus
(range 0.1–50 nM for TT cells and 0.1–100 nM for MZ-CRC-1 cells). The
plates were then placed in a 37C, 5% CO2 incubator. After 3 days, medium
was refreshed and everolimus was added again. After 6 days of treatment
cells were harvested for cell viability assay. A 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay was used to analyse the
effect of everolimus on cell viability. This assay is based on a colourimet-
ric method in which tetrazolium salt MTT (5 mg/ml in PBS) is added in the
plates for 3 hrs to be reduced into coloured formazan compounds by mito-
chondrial enzymes. It is solubilized with ethanol:DMSO (1:1) solution, and
the absorbance of the converted dye is measured at a wavelength of 570 nm
with background subtraction at 540 nm, using ELx800 Absorbance
Microplate Reader (Bio Tek Instrument, Winooski, VT, USA). All assays
were performed in six replicates and were repeated at least three times.
Calcitonin secretion
TT and MZ-CRC-1 cells were plated in 96-well plates at a density of 
3.5  104 per well. The following day, cell culture medium of both cell lines
was replaced with medium containing various concentrations of
everolimus (0.5, 1, 2 and 10 nM for TT cells and 1, 10 and 50 nM for MZ-
CRC-1). After 3 and 5 days, medium was changed with fresh medium with-
out (control group) or with everolimus. After 6 days conditioned medium
was collected to measure calcitonin levels through the CLT-LIAISON kit
(DiaSorin Inc., Stillwater, MN, USA), which employs a chemiluminescent
immuno assay. The results were obtained by determining the mean value
of six replicates, and the experiments were repeated at least three times.
The data were corrected for the effect of treatment on cell number.
Cell cycle analysis
TT and MZ-CR-1 cells were plated in duplicates in six-well plates at density
of 3  105 cell/well. The following day, cell culture medium of both cell lines
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was replaced with medium containing everolimus at the concentration of
5 and 50 nM, respectively in TT and MZ-CRC-1 cells. After 3 days, medium
was changed with fresh medium without (control group) or with
everolimus. After 6 days, cells were harvested by gentle trypsinization,
washed three times with cold PBS (calcium and magnesium free), and col-
lected by centrifugation at 1200 g for 5 min. The pellets were resuspended
in and directly stained with propidium iodide (PI; Sigma-Aldrich, St. Louis,
MO, USA) staining solution (50 g/ml PI, 0.6 g/ml RNase A and 0.05%
Triton X-100 in 0.1% sodium citrate) and incubated at 4C for 30 min. To
evaluate cell-cycle PI, for each tube, 10,000 cells were immediately meas-
ured and fluorescence was collected as FL1-A with a FACScalibur flow
cytometer (Becton Dickinson, Erembodegem, Belgium) using Cell Quest
Pro Software, as previously described [19].
Flow cytometric analysis of apoptosis
The effect of everolimus on apoptosis was analysed by AnnexinV-FITC and
PI staining. TT and MZ-CRC-1 (3  105 cells/well) were plated in six-well
plates and treated with everolimus, as previously described in the section
of cell cycle analysis. After 3 and 6 days cells were harvested by gentle
trypsinization, washed three times with cold PBS (calcium and magnesium
free; Sigma-Aldrich), and collected by centrifugation at 1200  g for 5 min.
The pellets were re-suspended in 1 binding buffer (0.1M Hepes/NaOH
(pH 7.4), 1.4M NaCl, 25 mM CaCl2) at a concentration of 1  106 cells/ml.
Cells (1  105 cells) were stained with 5 l of Annexin V-FITC (BD
Pharmingen, San Diego, CA, USA) and 10 l PI (50 g/ml in PBS). After
15 min. of incubation at room temperature in dark, 400 l of 1 binding
buffer were added to each tube. The analysis was performed by
FACScalibur at 10,000 events for each sample. With the use of CellQuest
Pro Software, three subsets of cells, based on intensity of staining with
Annexin and PI, were identified: Annexin/PI (live cells), Annexin/PI
(early apoptotic cells), and Annexin/PI (late apoptotic and necrotic
cells). Subsequently, the percentage of each population was calculated, as
previously described [20].
Western blot analysis
TT and MZ-CRC-1 cells after 3 and 6 days of incubation with everolimus,
respectively at the concentration of 5 and 50 nM, were scraped, washed twice
in cold PBS and resuspended in lysis buffer containing 150 mM NaCl, 10 mM
Tris-HCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol, 5 g/ml leupeptin, 
2 g/ml aprotinin, 5 mM Na4P2O7 and 1 mM Na3VO4. Cellular debris were
pelleted by centrifugation at 13,000  g for 15 min. at 4C and the super-
natant was collected for protein analysis. Cell extracts (30 g/lane) were
resolved on a 10% SDS-PAGE, transferred to nitrocellulose sheets at 100 mA
for 1.5 hr, and probed with specific antibodies: anti-caspase 3, anti-caspase
8, anti-caspase 9 and poly(ADP-ribose) polymerase (PARP) (Cell Signaling
Technology, Beverly, MA, USA). Blots were then developed using enhanced
chemo-luminescence detection reagents and exposed to X-ray film.
Senescence-associated -galactosidase staining
TT and MZ-CRC-1 cells were plated in six-well plates at a density of 2.5 
105 per well. The following day, cell culture medium of both cell lines was
replaced with medium containing everolimus at a concentration of 5 and
75 nM, respectively, in TT and MZ-CRC-1. After 3 days plates were
refreshed and everolimus was added again. After 6 days of treatment, cells
were washed with PBS and fixed with 2% formaldehyde, 0.2% glutaralde-
hyde in PBS for 5 min. at room temperature. Then, cells were washed 
twice with PBS and incubated at 37C (no CO2) with fresh senescence-
associated- galactosidase stain solution: 1 mg/ml X-Gal, 5 mM potassium
ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl, 2 mM MgCl2
and 30 mM citric acid/phosphate buffer (0.1M citric acid and 0.2M
Na2HPO4). Staining was evident in 1.5 hr for TT and 3 hrs for MZ-CRC1.
-Galactosidase positive cells were detected and counted by light
microscopy. For each determination, in 30 randomly selected fields at 20
magnification -galactosidase positive and negative cells were counted
twice. The number of positive (blue) cells was divided by the total number
of counted cells resulting in the percentage of -galactosidase positive
cells. Values of experiments in triplicates were averaged.
Statistical analysis
The comparative statistical evaluation among groups was first performed
by the ANOVA test. When significant differences were found, a comparison
between groups was made using the Newman–Keuls test. Student’s t-test
was used to assess differences between two groups. In all analyses, val-
ues of P  0.05 were considered statistically significant. Data are reported
as mean 	 S.E.M.
Case report
Patient 1 (a 60-yr-old male) had a clinical diagnosis of MTC in
1999 on the basis of evidence of cervical enlargement, associated
to high serum concentrations of calcitonin (185 pg/ml), thyroid
nodules and cervical lymph node enlargement at the neck ultra-
sonography. An intervention of thyroidectomy plus central and 
left latero-cervical lymph node dissection was performed and
 histology confirmed the diagnosis of MTC with lymph node
 metastases. After surgery, there was persistence of high serum
calcitonin concentrations. In 2004, tumour progression occurred
with appearance of bone metastases and, subsequently in 2006,
with the onset of palpable right latero-cervical lymph node
enlargement leading to a second surgery for removal of lymph
node metastases. Bone pain was initially controlled by a treatment
with zoledronic acid (4 mg a month i.v.) since September 2005.
Because of the progressive worsening of clinical symptoms
related to bone metastases, a treatment with octreotide LAR 
30 mg a month was started in 2006 with poor relief on symptoms.
Because an Indium-111-DTPA-Phe1-octreotide Octreoscan
(Mallinckrodt Medical, Petten, The Netherlands; 120–200 MBq)
was positive in correspondence of vertebral metastases (Krenning
score grade 3), three cycles of radio-labelled somatostatin ana-
logue therapy with 90Y-Dotatate were performed in 2006–2007.
No significant relief of bone symptoms was observed and a
marked progression of vertebral metastases with spinal cord com-
pression and onset of paraplegia and parasthesia occurred in
2008. For this reason, 10 sessions of external radiotherapy for a
cumulative radiant dose of 30 Gy were performed in May and June
2008 to treat vertebral metastases of the dorsal tract (D4–D6).
However, bone symptoms and signs persisted unmodified and a
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further tumour progression at skeletal level was observed at the
MRI evaluation. In December 2008, everolimus was started at the
dose of 10 mg a day per os under compassionate use.
Patient 2 (a 74-yr-old male) had a clinical diagnosis of MTC in
1974. Medullary thyroid cancer was revealed by appearance of 
cervical enlargement, associated to thyroid nodules at the neck
ultrasonography and high serum concentration of calcitonin 
(215 pg/ml). A total thyroidectomy was performed and the diag-
nosis of MTC was confirmed at the pathological examination.
After surgery, serum calcitonin levels were still positive and
progressively increasing. Two other operations were performed
in 2001 and 2007 to remove lymph node metastases detected at
the right and left latero-cervical compartments. Post-operative
follow-up revealed persistence of high serum calcitonin concen-
trations and evidence of cervical and mediastinal lymph node
metastases and bone metastases associated to clinical symptoms
(diarrhoea, flushing and bone pain).
In March 2008, a treatment with octreotide LAR 30 mg a
month was started resulting in mild improvement of diarrhoea and
flushing but progressive worsening of bone pain from vertebral
metastases. A treatment with zoledronic acid (4 mg a month i.v.)
was started in October 2008 and discontinued in December 2008
because of insurgence of severe gastro-intestinal symptoms at
each administration. In February 2009, everolimus was started at
the dose of 5 mg a day per os under compassionate use.
Results
In vivo anti-proliferative and anti-secretive effects
of everolimus
Patient 1 had a rapid serum calcitonin decrease 1 month after the
start of everolimus, then the levels moderately raised again at 
2 month follow-up, after 2 weeks of drug discontinuation for
haematological toxicity (grade 3 thrombocytopenia and grade 
Fig. 1 Calcitonin and CEA serum concentrations in Patient 1 (A, C) and Patient 2 (B, D) because the start of the treatment with octreotide LAR 30 mg a
month and then during treatment with everolimus at different doses.
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2 anaemia) and resumption of everolimus treatment at a dose of 
5 mg a day for 2 other weeks (Fig. 1A and C). Because the third
month of treatment, everolimus was given at the dose of 10 mg a
day resulting in a progressive decrease of calcitonin until the 5-
month follow-up. Since month 6, the dose was lowered to 5 mg a
day for 2 months and then to 5 mg every other day because of
grade 2 thrombocytopenia and grade 3 abdominal toxicity, includ-
ing nausea, diarrhoea and abdominal pain. This change in the dose
of everolimus resulted in a mild and progressive increase of calci-
tonin concentration. Serum CEA variations after treatment paralled
at a lower extent CT variations along the follow-up.
At the morphological evaluation, skeletal MRI was substan-
tially unchanged after 6 months of treatment with everolimus;
however, a mild decrease was reported for vertebral lesions of
the lumbar tract. Neurological symptoms were consistent with
paraplegia and incapacity of bladder empting with necessity of
urinary catheterization at the beginning of everolimus treatment.
Both paraplegia and bladder dysfunction markedly improved 
1 month after treatment with partial recovery of walking and
bladder function. This condition was maintained for 6 months.
After everolimus dose decrease and then discontinuation,
 paraplegia and bladder dysfunction relapsed and progressively
worsened along the follow-up.
Everolimus was withdrawn by the patient himself in December
2009 after 1 year of treatment due to a further tumour progression
at skeletal level with involvement of all vertebral bodies and skull
and consequent worsening of neurological symptoms.
Patient 2 received initially everolimus at the dose of 5 mg a day
because of a mild chronic anaemia (haemoglobin: 10.5 g/dl) sug-
gesting not to administrate the full dose of 10 mg a day. As the drug
was clinically and biochemically well-tolerated, since month 2 the
dose was increased to 10 mg a day. This change in the dose of
everolimus resulted in a marked decrease of serum calcitonin,
which was substantially unchanged after the first month of treat-
ment with 5 mg a day (Fig. 1B and D). Serum CEA levels were even
increased under everolimus 5 mg a day as compared to baseline
and mildly decreased after increasing the dose to 10 mg. Then,
because of insurgence of grade 2 anaemia and grade 3 neutropenia
with fever and need of antibiotic therapy, everolimus was
 discontinued until recovery to grade 1 haematological toxicity. Since
month 6, everolimus was restarted to 5 mg a day resulting in stable
calcitonin concentrations and variable CEA concentrations with ini-
tial decrease and subsequent regrowth. Since month 13, everolimus
was increased to 10 mg a day resulting in a progressive decrease of
calcitonin and CEA concentrations. The treatment with everolimus
was still ongoing at the last follow-up at the same dose with good
tolerance. After the beginning of everolimus, no diarrhoea and flush-
ing were complained by the patient while bone pain was quite well-
controlled only requiring short-time treatment with oral analgesics.
At the skeletal MRI, vertebral lesions were substantially
unchanged after 6 months of treatment with everolimus, then
increased in number at 12-month follow-up but not further pro-
gressed at 18-month follow-up. At the multislice CT scan, medi-
astinal lymph node metastases were unchanged in size along the
follow-up; however, a large area of necrosis was evident within the
biggest lesion at pre-vascular level since the first CT evaluation 
3 months after the beginning of everolimus treatment. At the
colour Doppler ultrasonography, a dramatic change of tumour
vascularization was observed in the laterocervical lymph node
metastases (Fig. 2), with a mild decrease in the left laterocervical
lymph node metastasis after treatment as compared to baseline
(15 mm versus 22 mm, respectively).
In vitro anti-proliferative and anti-secretory
effects of everolimus
Everolimus significantly suppressed the growth of TT cells
[median inhibition concentration (IC50) 0.33 nM, maximal inhibi-
tion of proliferation: 48%] in a dose-dependent manner after 
6 days of incubation (Fig. 3A). The anti-proliferative effect of
everolimus was less prominent in MZ-CRC-1 cell line, as shown
by the higher IC50 (2.3 nM) and lower maximal inhibition of prolif-
eration (22.5%) compared to TT cells (Fig. 3B). Incubation of TT
cells (Fig. 3C) and MZ-CRC-1 (Fig. 3D) with everolimus for 6 days
did not significantly affect calcitonin secretion.
Fig.  2 Colour Doppler ultrasonography
imaging of a laterocervical lymph node
metastasis before (A) and after 3 months of
treatment with everolimus 10 mg a day (B).
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Effects of everolimus on the cell-cycle
After 6 days of incubation, everolimus (5 nM) induced a significant
accumulation of TT cells in G0/G1 phase (13%, P 
 0.05; 
Fig. 4A) and decreased the fraction of cells in S phase (35%, 
P 0.001; Fig. 4B) compared with the control. Similarly, everolimus
(75 nM) increased the percentage of MZ-CRC-1 cells in G0/G1
phase (18%, P  0.05; Fig. 4C) and decreased the fraction of
cells in S phase (40%, P  0.001; Fig. 4D).
Effects of everolimus on apoptosis
In TT and MZ-CRC-1 cells, the effects on the apoptosis of 6 days
of treatment with everolimus, respectively at the concentrations of
5 and 75 nM, were examined by flow cytometry with Annexin V
and propidium iodide. No significant change in the percentage of
early and late apoptotic cells was observed during incubation with
everolimus compared to control in both cell lines. To exclude any
effect of everolimus on apoptosis, we investigated the activation of
caspase-3, caspase-8, caspase-9 and PARP. After 6 days of 
incubation everolimus did not modify the expression of cleaved
caspases and PARP in both cells compared to untreated cells.
Figure 5 shows the effects of everolimus on apoptosis in MZ-CRC-
1 after 6 days of incubation with everolimus, similar results were
observed in TT cells and after 3 days of incubation in both cell
lines (data not shown).
Effects of everolimus on senescence
To evaluate the effects of mTOR inhibitors on cellular senescence,
TT and MZ-CRC-1 cells were treated with everolimus at the con-
centrations of 5 and 75 nM, respectively. As shown in Figure 6A,
analysis of senescence based on cellular -galactosidase activity
revealed that the percentage of senescent TT cells to be doubled
after everolimus treatment compared to the control (14.6 	 3.3%
and 7.2 	 1.3%, respectively, P  0.001). Although in MZ-CRC-1
Fig. 3 Effects of 6 days of incubation with or without everolimus on cell proliferation (A, B) and CT secretion (C, D) in TT (A, C) and MZ-CRC-1 (B, D).
Values are expressed as the percentage of control (untreated cells) and represent the mean 	 S.E.M. of at least three independent experiments in six
replicates. *P  0.001 and **P  0.05 versus control.
J. Cell. Mol. Med. Vol 16, No 7, 2012
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Fig. 4 Cell cycle analysis of TT (A, B) and
MZ-CRC-1 (C, D) cells after 6 days of incu-
bation with everolimus, respectively at the
concentrations of 5 and 75 nM. Data are
expressed as mean 	 S.E.M. of the percent-
age of cells in the G0/G1 (A, C) and S (B, D)
phase of three independent performed
experiments, as compared with untreated
control cells. Control values have been set to
100%. *P 
 0.05, **P  0.05 and ***P 
0.001 versus untreated control.
Fig. 5 Effect of everolimus on apoptosis in human MZ-CRC-1 cell line. MZ-CRC-1 cells were incubated with 75 nM of everolimus for 6 days. Subsequently,
the proportions of cells in early (A) and late (B) apoptosis were analysed by flow cytometry. Values are demonstrated as average and S.E.M. of three inde-
pendent performed experiments. During this experiment total cell lysates were analysed by Western blot to detect the cleavage of caspases 3, 8, 9 and
PARP (C). Actin was used as control for equal lading.
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there was no significant increase of senescent cells after
everolimus treatment (Fig. 6B).
Discussion
Approximately 50% of the patients with MTC has persistent or
relapsing disease after surgery. Although MTC is a slowly growing
tumour, more than half of patients with advanced MTC will not
survive beyond 10 years [1, 2]. Considering that surgery is the
only curative approach for these patients and no effective therapy
exists for metastatic disease, a novel agent, with a potential anti-
secretive and anti-proliferative activity in MTC, may represent a
consistent therapeutic advance. A new clinical scenario is now
emerging because of the availability of different compounds,
which target specific molecular pathways. In the field of hereditary
MTC, interesting data have been recently reported by using vande-
tanib, a selective oral inhibitor of RET, vascular endothelial growth
factor receptor, and epidermal growth factor receptor signalling
[21]. On the basis of investigator assessments, 20% of patients
(i.e. six of 30 patients) experienced a confirmed partial response
(median duration of response at data cut-off, 10.2 months). An
additional 53% of patients (i.e. 16 of 30 patients) experienced sta-
ble disease at 24 weeks, which yielded a disease control rate of
73% (i.e. 22 of 30 patients). The authors concluded that vande-
tanib may provide an effective therapeutic option in patients with
advanced hereditary MTC.
Because MTC belongs to the family of neuroendocrine tumours,
it has been also investigated for the expression of somatostatin
receptors, the key molecules allowing somatostatin analogues to
exert their anti-tumour activity [3, 4]. However, no anti-tumour
effects have been observed in MTC patients treated with octreotide
and lanreotide, the actually available somatostatin analogues [5–8].
AKT-mTOR pathway has been demonstrated to be overexpressed
in neuroendocrine tumours as well as everolimus, a mTOR
inhibitor, was demonstrated to be effective in neuroendocrine
tumour cell lines [10, 13]. In a recent in vitro study on MTC,
everolimus significantly inhibited cell viability in a dose- and time-
dependent manner. It diminished phosphorylation of mTOR and
p70S6K in both TT cells and cultured human MTCs, induced cell
cycle arrest in the G0/G1 phase in TT cells, but had no effect on
apoptosis [18]. Interestingly, another study highlighted that the
combination of everolimus with octreotide/pasireotide was
 significantly more anti-proliferative than either agent alone in neu-
roendocrine tumour cell lines. The dose-dependent increase of Akt
phosphorylation observed with everolimus was completely inhib-
ited by the combination therapy [13]. Furthermore, in patients with
digestive neuroendocrine tumours, the combination therapy
everolimus/octreotide was reported to have important effects on
tumour proliferation, resulting in objective tumour response and
stabilization in about 20% and 70% of cases, respectively [14].
In this study, everolimus showed to induce significant anti-
 proliferative effects in both TT and MZ-CRC-1 MTC cell lines. This
anti-tumour activity seems to be mediated by the induction of cell
cycle arrest in G0/G1 phase, but not of apoptosis. Beyond the apop-
tosis it is emerging recently that senescence could be a potential
endpoint for tumour therapy [22]. Cellular senescence is an
 irreversible growth arrest, preferentially in G1 phase, that limits the
lifespan of mammalian cells and prevents unlimited cell prolifera-
tion protecting against the development and progression of cancer.
Senescent cells are unable to divide, penetrate the surrounding tis-
sues and metastasize [23]. In humans, the role of mTOR in
longevity and cellular senescence is complex [24, 25]. It has been
suggested that activation of p53 induces cell cycle arrest, after
which its ability to exercise senescence or quiescence is dependent
on its interaction with the mTOR pathway [26]. On the other hand,
Ota et al. recently described that everolimus induces senescence
involving down-regulation of Sirtuin 1 in human endothelial cells
Fig. 6 Effect of everolimus on cellular senescence. TT (A) and MZ-CRC-1 (B) cells were treated with everolimus for 6 days at the concentrations of 5 and
75 nM, respectively, and then were stained for -galactosidase. The results were reported as the percentage of -galactosidase positive cells. The exper-
iments were repeated at least three times. *P  0.001.
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[27]. In our study we showed that everolimus induced senescence
exclusively in TT cells, as shown by the significant increase in -
galactosidase positive cells during incubation with mTOR inhibitor.
This could partially explain the better anti-proliferative activity of
everolimus in TT cells compared to MZ-CRC-1. However, we can-
not exclude that additional indirect mechanisms (effects on growth
factors production, inhibition of angiogenesis, etc.) are involved in
the anti-tumour activity of everolimus in MTC. Moreover, because
we have exposed MTC cells to everolimus for a long incubation
time, we cannot exclude that secondary necrosis occurred aside
senescence. However, our findings suggest a relevant, even if not
necessarily unique, role of senescence in the biological effects
observed in our experimental conditions.
Finally, everolimus in combination with octreotide was evalu-
ated for the first time in the treatment of patients with MTC. In this
preliminary observation, calcitonin hypersecretion was signifi-
cantly decreased in both patients under study, while CEA decrease
paralleled calcitonin variations but at a lower extent. Since
everolimus did not result in a significant inhibition of calcitonin
secretion on MTC cell lines, the decrease of serum calcitonin con-
centrations observed during treatment with everolimus may be
explained by a potent anti-tumour activity of this agent. In fact, a
tumour response was observed in both patients, as expressed by
indirect signs of inhibition of bone metastases, such as decrease
of nerve compression and improvement of paraplegia in patient 1,
tumour necrosis and decrease in tumour size and vascularization
of lymph node metastases in patient 2.
A relevant point is that all the anti-proliferative effects were
observed when everolimus was given at the full dose of 10 mg a
day and not when a lower dose was administered. On the other
hand, the continuous administration of everolimus 10 mg a day
resulted in grades 2–3 side effects which required dose reduction.
Perhaps a helpful option could be to start the treatment with lower
dose of everolimus, less active on tumour growth but being able
to induce a gradual patient adaptation to the drug toxicity, and then
to switch to the full dose to obtain prolonged anti-proliferative
effects. In this study, patient 2 experienced more gradual but more
durable anti-secretive and anti-proliferative effects than patient 1
and this may in part reflect the different modality of administration
of everolimus. It would be also crucial to introduce this treatment
in a early stage of disease when patient conditions are less
 compromised by tumour spread. The clinical results of this report
are only preliminary and need to be confirmed by clinical trials on
a larger series of patients that we are beginning to enrol in an
ongoing clinical trial in our institutions.
In conclusions, this study reports for the first time that
everolimus in combination with octreotide may be effective as
anti-tumour therapy in patients with progressive and metastatic
MTC, suggesting to perform further larger studies to confirm
these potential effects.
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